AR051296A1 - Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6h-azepino(5,4,3-cd)indol-6-ona - Google Patents
Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6h-azepino(5,4,3-cd)indol-6-onaInfo
- Publication number
- AR051296A1 AR051296A1 ARP050103934A ARP050103934A AR051296A1 AR 051296 A1 AR051296 A1 AR 051296A1 AR P050103934 A ARP050103934 A AR P050103934A AR P050103934 A ARP050103934 A AR P050103934A AR 051296 A1 AR051296 A1 AR 051296A1
- Authority
- AR
- Argentina
- Prior art keywords
- azepino
- tetrahydro
- fluoro
- phenyl
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
La presente se refiere a nuevas formas polimorficas i amorfas de la sal fosfato de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6H-azepino[5,4,3-cd]indol-6-ona, y a procedimientos para su preparacion. Tales formas polimorficas pueden ser un componente e una composicion farmacéutica y se pueden usar para tratar una enfermedad en un mamífero mediada por la actividad de la poli(ADP-ribosa)-polimerasa, incluyendo enfermedades tales como el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61245904P | 2004-09-22 | 2004-09-22 | |
US67929605P | 2005-05-09 | 2005-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR051296A1 true AR051296A1 (es) | 2007-01-03 |
Family
ID=35526956
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050103934A AR051296A1 (es) | 2004-09-22 | 2005-09-20 | Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6h-azepino(5,4,3-cd)indol-6-ona |
Country Status (18)
Country | Link |
---|---|
US (1) | US7268126B2 (es) |
EP (1) | EP1799685B1 (es) |
JP (1) | JP2008513436A (es) |
KR (1) | KR100853601B1 (es) |
AR (1) | AR051296A1 (es) |
AT (1) | ATE551345T1 (es) |
AU (1) | AU2005286191B2 (es) |
BR (1) | BRPI0516766A (es) |
CA (1) | CA2581025C (es) |
ES (1) | ES2382950T3 (es) |
HK (1) | HK1116483A1 (es) |
IL (1) | IL181463A (es) |
MX (1) | MX2007002461A (es) |
NO (1) | NO337938B1 (es) |
NZ (1) | NZ554659A (es) |
RU (1) | RU2355691C2 (es) |
TW (1) | TWI365188B (es) |
WO (1) | WO2006033007A2 (es) |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1611137A1 (en) * | 2003-03-31 | 2006-01-04 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
US8425929B2 (en) * | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
JP5177429B2 (ja) * | 2005-07-18 | 2013-04-03 | バイパー サイエンシズ,インコーポレイティド | 癌の治療 |
US20100279327A1 (en) * | 2006-06-12 | 2010-11-04 | Bipar Sciences, Inc. | Method of treating diseases with parp inhibitors |
CN101522609A (zh) * | 2006-09-05 | 2009-09-02 | 彼帕科学公司 | 癌症的治疗 |
US7994222B2 (en) * | 2006-09-05 | 2011-08-09 | Bipar Sciences, Inc. | Monitoring of the inhibition of fatty acid synthesis by iodo-nitrobenzamide compounds |
WO2008114114A2 (en) * | 2007-03-16 | 2008-09-25 | Pfizer Products Inc. | Poly(adp-ribose) polymerases inhibitor for treating ophthalmic condition |
CA2705417A1 (en) * | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents |
US7732491B2 (en) * | 2007-11-12 | 2010-06-08 | Bipar Sciences, Inc. | Treatment of breast cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
CN101888777A (zh) * | 2007-12-07 | 2010-11-17 | 彼帕科学公司 | 用拓扑异构酶抑制剂和parp抑制剂的组合治疗癌症 |
EP2250282A4 (en) * | 2008-02-04 | 2011-05-18 | Bipar Sciences Inc | METHOD FOR THE DIAGNOSIS AND TREATMENT OF PARP-MEDIATED DISEASES |
JP5982287B2 (ja) | 2009-11-09 | 2016-08-31 | アラーガン、インコーポレイテッドAllergan,Incorporated | 発毛を刺激する組成物および方法 |
DK3150610T3 (da) * | 2010-02-12 | 2019-11-04 | Pfizer | Salte og polymorfer af 8-fluor-2-{4-[(methylamino}methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-on |
CA2798697A1 (en) | 2010-05-10 | 2011-11-17 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
RU2641021C2 (ru) | 2013-02-15 | 2018-01-17 | Аллерган, Инк. | Имплантат для пролонгированной доставки лекарственного средства |
TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
CN108138177B9 (zh) | 2015-07-23 | 2021-08-13 | 法国居里学院 | Dbait分子与PARP抑制剂的组合用于治疗癌症的用途 |
GB201519573D0 (en) | 2015-11-05 | 2015-12-23 | King S College London | Combination |
WO2018140377A1 (en) | 2017-01-24 | 2018-08-02 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib and of rucaparib salts |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2018218025A1 (en) * | 2017-05-24 | 2018-11-29 | The Trustees Of The University Of Pennsylvania | Radiolabeled and fluorescent parp inhibitors for imaging and radiotherapy |
EP3704124A1 (en) | 2017-11-03 | 2020-09-09 | Sandoz AG | Crystalline salt of a tricyclic poly(adp-ribose) polymerase inhibitor |
CN111989137A (zh) | 2018-01-05 | 2020-11-24 | 赛博克萨1公司 | 用于治疗涉及酸性或缺氧性患病组织的疾病的化合物、组合物和方法 |
US10442813B2 (en) | 2018-01-30 | 2019-10-15 | RK Pharma Solutions LLC | Polymorphs of rucaparib camsylate and methods of making same |
US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
BR112022000297A2 (pt) | 2019-07-10 | 2022-03-15 | Cybrexa 3 Inc | Conjugados de peptídeos de agentes de alvo de microtúbulos como terapêuticos |
CN114341162A (zh) | 2019-07-10 | 2022-04-12 | 赛博克萨2公司 | 作为治疗剂的细胞毒素的肽缀合物 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
EP4100125A1 (en) | 2020-02-03 | 2022-12-14 | Sandoz AG | Polymorph of rucaparib mesylate |
WO2021220120A1 (en) | 2020-04-28 | 2021-11-04 | Rhizen Pharmaceuticals Ag | Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors |
WO2022015557A1 (en) | 2020-07-14 | 2022-01-20 | Assia Chemical Industries Ltd | Solid state forms of rucaparib salts |
WO2022090938A1 (en) | 2020-10-31 | 2022-05-05 | Rhizen Pharmaceuticals Ag | Phthalazinone derivatives useful as parp inhibitors |
WO2022215034A1 (en) | 2021-04-08 | 2022-10-13 | Rhizen Pharmaceuticals Ag | Inhibitors of poly(adp-ribose) polymerase |
WO2023137060A1 (en) | 2022-01-11 | 2023-07-20 | Assia Chemical Industries Ltd. | Solid state forms of rucaparib tosylate |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI20691B (sl) | 1999-01-11 | 2008-10-31 | Agouron Pharma | Triciklični inhibitorji poli(ADP-riboza) polimeraz |
EP1611137A1 (en) * | 2003-03-31 | 2006-01-04 | Pfizer Inc. | Salts of tricyclic inhibitors of poly(adp-ribose) polymerases |
KR101138471B1 (ko) * | 2003-07-25 | 2012-04-25 | 화이자 인코포레이티드 | 트리시클로 parp 저해제 |
-
2005
- 2005-09-12 AT AT05799991T patent/ATE551345T1/de active
- 2005-09-12 MX MX2007002461A patent/MX2007002461A/es active IP Right Grant
- 2005-09-12 BR BRPI0516766-3A patent/BRPI0516766A/pt not_active Application Discontinuation
- 2005-09-12 AU AU2005286191A patent/AU2005286191B2/en active Active
- 2005-09-12 EP EP05799991A patent/EP1799685B1/en active Active
- 2005-09-12 CA CA2581025A patent/CA2581025C/en active Active
- 2005-09-12 ES ES05799991T patent/ES2382950T3/es active Active
- 2005-09-12 NZ NZ554659A patent/NZ554659A/en unknown
- 2005-09-12 RU RU2007110026/04A patent/RU2355691C2/ru active
- 2005-09-12 JP JP2007531869A patent/JP2008513436A/ja active Pending
- 2005-09-12 KR KR1020077006422A patent/KR100853601B1/ko active IP Right Grant
- 2005-09-12 WO PCT/IB2005/002941 patent/WO2006033007A2/en active Application Filing
- 2005-09-20 AR ARP050103934A patent/AR051296A1/es unknown
- 2005-09-21 US US11/233,835 patent/US7268126B2/en active Active
- 2005-09-21 TW TW094132634A patent/TWI365188B/zh active
-
2007
- 2007-02-16 NO NO20070920A patent/NO337938B1/no unknown
- 2007-02-20 IL IL181463A patent/IL181463A/en active IP Right Grant
-
2008
- 2008-06-20 HK HK08106859.9A patent/HK1116483A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
NZ554659A (en) | 2010-08-27 |
HK1116483A1 (es) | 2008-12-24 |
AU2005286191A1 (en) | 2006-03-30 |
JP2008513436A (ja) | 2008-05-01 |
RU2355691C2 (ru) | 2009-05-20 |
AU2005286191B2 (en) | 2011-11-17 |
CA2581025A1 (en) | 2006-03-30 |
WO2006033007A3 (en) | 2006-11-02 |
US7268126B2 (en) | 2007-09-11 |
WO2006033007A2 (en) | 2006-03-30 |
US20060100198A1 (en) | 2006-05-11 |
KR20070089121A (ko) | 2007-08-30 |
EP1799685A2 (en) | 2007-06-27 |
KR100853601B1 (ko) | 2008-08-22 |
IL181463A (en) | 2012-02-29 |
ES2382950T3 (es) | 2012-06-14 |
IL181463A0 (en) | 2007-07-04 |
ATE551345T1 (de) | 2012-04-15 |
CA2581025C (en) | 2011-06-07 |
TW200613305A (en) | 2006-05-01 |
BRPI0516766A (pt) | 2008-09-16 |
RU2007110026A (ru) | 2008-10-27 |
NO20070920L (no) | 2007-03-15 |
EP1799685B1 (en) | 2012-03-28 |
MX2007002461A (es) | 2008-03-13 |
TWI365188B (en) | 2012-06-01 |
NO337938B1 (no) | 2016-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR051296A1 (es) | Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-(4-((metilamino)metil)fenil)-1,3,4,5-tetrahidro-6h-azepino(5,4,3-cd)indol-6-ona | |
AR080164A1 (es) | Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona | |
BRPI0917119A2 (pt) | composto, composição farmacêutica, métodos para inibir a poli(adp-ribose) polimerase em um paciente, para tratar uma doença, uso de um composto, e, artigo de fabricação. | |
LTPA2017009I1 (lt) | Brutono tirozinkinazės inhibitoriai | |
CL2007002018A1 (es) | Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular. | |
MX2020012868A (es) | Metodos y composiciones para trastornos del sue?o y otros trastornos. | |
EA201001256A1 (ru) | Производные диазаспиро[5.5]ундекана в качестве антагонистов мускариновых рецепторов и агонистов бета-адренорецепторов для применения в лечении легочных расстройств | |
EP3037421A3 (en) | Mlk inhibitors and methods of use | |
BR112012018386A8 (pt) | "inibidores isoindolinona de fosfatidilinositol 3-quinase" | |
WO2006076620A3 (en) | Bendamustine pharmaceutical compositions for lyophilisation | |
CL2007003635A1 (es) | Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer. | |
DK1812440T3 (da) | Pyrazolo[1,5-a]pyrimidiner, der kan anvendes som inhibistorer af proteinkinaser | |
AR051099A1 (es) | Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas | |
CR10211A (es) | Compuestos de tiazol y métodos de uso | |
WO2006053049A3 (en) | Herbal composition phy906 and its use in chemotherapy | |
NO20084853L (no) | Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni | |
WO2007076161A3 (en) | Compounds with therapeutic activity | |
DE602007012473D1 (de) | Als proteinkinaseinhibitoren geeignete verbindungen | |
NI200800175A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento de abuso y adicción de sustancias. | |
DE602006017574D1 (de) | Als protein-kinase-inhibitoren nutzbare benzimidazole | |
AR052322A1 (es) | Compuestos de n-benzoil-estaurosporina, procesos para su preparacion y composicion farmaceutica | |
WO2009085271A3 (en) | Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of orthopedic conditions | |
CL2007002511A1 (es) | Compuestos derivados de pirrolo[2,3-f]isoquinolina, inhibidores de cinasa-2; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de una enfermedad autoinmune. | |
CL2007002195A1 (es) | Compuesto n-((1r,2s,5r)-5-(isopropil(metil)amino)-2-((s)-2-oxo-3-(6-(trifluorometil)quinazolin-4-ilamino)pirrolidin-1-il)ciclohexil)acetamida; forma cristalina del compuesto; composicion farmaceutica; y uso en el tratamiento de enfermedades tales com | |
CL2008002060A1 (es) | Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |